Literature DB >> 16966691

MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior.

Claudia Roldo1, Edoardo Missiaglia, John P Hagan, Massimo Falconi, Paola Capelli, Samantha Bersani, George Adrian Calin, Stefano Volinia, Chang-Gong Liu, Aldo Scarpa, Carlo M Croce.   

Abstract

PURPOSE: We investigated the global microRNA expression patterns in normal pancreas, pancreatic endocrine tumors and acinar carcinomas to evaluate their involvement in transformation and malignant progression of these tumor types. MicroRNAs are small noncoding RNAs that regulate gene expression by targeting specific mRNAs for degradation or translation inhibition. Recent evidence indicates that microRNAs can contribute to tumor development and progression and may have diagnostic and prognostic value in several human malignancies.
MATERIALS AND METHODS: Using a custom microarray, we studied the global microRNA expression in 12 nontumor pancreas and 44 pancreatic primary tumors, including 12 insulinomas, 28 nonfunctioning endocrine tumors, and four acinar carcinomas.
RESULTS: Our data showed that a common pattern of microRNA expression distinguishes any tumor type from normal pancreas, suggesting that this set of microRNAs might be involved in pancreatic tumorigenesis; the expression of miR-103 and miR-107, associated with lack of expression of miR-155, discriminates tumors from normal; a set of 10 microRNAs distinguishes endocrine from acinar tumors and is possibly associated with either normal endocrine differentiation or endocrine tumorigenesis; miR-204 is primarily expressed in insulinomas and correlates with immunohistochemical expression of insulin; and the overexpression of miR-21 is strongly associated with both a high Ki67 proliferation index and presence of liver metastasis.
CONCLUSION: These results suggest that alteration in microRNA expression is related to endocrine and acinar neoplastic transformation and progression of malignancy, and might prove useful in distinguishing tumors with different clinical behavior.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16966691     DOI: 10.1200/JCO.2005.05.5194

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  295 in total

1.  miR-21 and miR-375 microRNAs as candidate diagnostic biomarkers in squamous cell carcinoma of the larynx: association with patient survival.

Authors:  An Hu; Jing-Juan Huang; Wei-Hua Xu; Xiao-Jie Jin; Ji-Ping Li; Yuan-Jia Tang; Xin-Fang Huang; Hui-Juan Cui; Guang-Bin Sun
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

2.  Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma.

Authors:  Ya-Hui Huang; Kwang-Huei Lin; Hua-Chien Chen; Ming-Ling Chang; Chao-Wei Hsu; Ming-Wei Lai; Tse-Ching Chen; Wei-Chen Lee; Yi-Hsin Tseng; Chau-Ting Yeh
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

Review 3.  The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases.

Authors:  John R Finnerty; Wang-Xia Wang; Sébastien S Hébert; Bernard R Wilfred; Guogen Mao; Peter T Nelson
Journal:  J Mol Biol       Date:  2010-08-01       Impact factor: 5.469

Review 4.  Implication of microRNAs in drug resistance for designing novel cancer therapy.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Dejuan Kong; Shadan Ali
Journal:  Drug Resist Updat       Date:  2010-03-17       Impact factor: 18.500

5.  Biological role of microRNA-103 based on expression profile and target genes analysis in pigs.

Authors:  Guoxi Li; Zongsong Wu; Xinjian Li; Xiaomin Ning; Yanjie Li; Gongshe Yang
Journal:  Mol Biol Rep       Date:  2010-12-09       Impact factor: 2.316

6.  MicroRNA cloning and sequencing in osteosarcoma cell lines: differential role of miR-93.

Authors:  Luisa Montanini; Lisa Lasagna; Valeria Barili; Søren Peter Jonstrup; Alba Murgia; Laura Pazzaglia; Amalia Conti; Chiara Novello; Jørgen Kjems; Roberto Perris; Maria Serena Benassi
Journal:  Cell Oncol (Dordr)       Date:  2011-09-30       Impact factor: 6.730

7.  Discordant expression of miR-103/7 and pantothenate kinase host genes in mouse.

Authors:  Brenda J Polster; Shawn K Westaway; Thuy M Nguyen; Moon Y Yoon; Susan J Hayflick
Journal:  Mol Genet Metab       Date:  2010-08-04       Impact factor: 4.797

8.  Clusterin is a gene-specific target of microRNA-21 in head and neck squamous cell carcinoma.

Authors:  Wojciech Mydlarz; Mamoru Uemura; Sun Ahn; Patrick Hennessey; Steven Chang; Semra Demokan; Wenyue Sun; Chunbo Shao; Justin Bishop; Julie Krosting; Elizabeth Mambo; William Westra; Patrick Ha; David Sidransky; Joseph Califano
Journal:  Clin Cancer Res       Date:  2013-12-10       Impact factor: 12.531

9.  microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.

Authors:  Aldo M Roccaro; Antonio Sacco; Changzhong Chen; Judith Runnels; Xavier Leleu; Feda Azab; Abdel Kareem Azab; Xiaoying Jia; Hai T Ngo; Molly R Melhem; Nicholas Burwick; Lyuba Varticovski; Carl D Novina; Barrett J Rollins; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

10.  Emerging role of microRNA-21 in cancer.

Authors:  Yin-Hsun Feng; Chao-Jung Tsao
Journal:  Biomed Rep       Date:  2016-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.